Raymond James Maintains Strong Buy Rating for CymaBay Therapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Raymond James has maintained its Strong Buy rating for CymaBay Therapeutics (NASDAQ:CBAY) and increased its price target from $33.00 to $34.00. This new target represents a 106.56% increase from the current share price. CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver and other chronic diseases.
November 08, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has maintained a Strong Buy rating for CymaBay Therapeutics and raised its price target, indicating a positive outlook for the company's stock.
The maintenance of the Strong Buy rating and the increase in price target by Raymond James indicates a positive outlook for CymaBay Therapeutics. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100